Loading...

Loading...

Adjust height of sidebar

KMap

People

Adjust height of sidebar

KMap

Profile

Picture of Monika Schmelz

Monika Schmelz

Professor, Pathology - (Research Scholar Track) | Professor, Applied BioSciences - GIDP | Professor, BIO5 Institute

Pathology and Lab Medicine

Collaboration(21)

Bonnie LaFleur
Fernando Martinez
Marlys Witte
David Besselsen
Russell Witte

Page 1 of 5

Grants(10)

Page 1 of 2

Publications(43)

Recent

Validation of Biorepository Quality: Accreditation

2023

biorepository quality, accreditation, validation, biological samples, quality assurance

Optimizing CD30 Expression in Hodgkin Lymphoma by Controlling for Low Expression

2023

hodgkin lymphoma, cd30 expression, optimization, controlling low expression, cancer immunotherapy

The AIDS and Cancer Specimen Resource ACSR) HIV malignancy specimens and data available at no cost.

2023

hiv, cancer, specimen, data, research

Biorepository best practices for research and clinical investigations.

2022

biorepository, clinical investigations, research best practices, biobanking, clinical research

Plan for Emergency Shutdown and Reopening for a Consortium of Biobanks

2021

emergency planning, biobank consortium, shutdown procedures, reopening protocol, risk management

HDAC inhibitors induce an MHCII positive phenotype with active lipid droplet formation in DLBCL cells

2018

cancer immunotherapy, cell biology, drug development, immunology, pharmacology

The Ins and Outs of Setting Ua Biorepository for Multi-Site Clinical Trials

2018

biorepository, clinical trials, multi-site, setting up, ins and outs

Phase 1 study of the investigational aurora A kinase inhibitor alisertib rituximab or rituximab/vincristine in relapsed or refractory aggressive B-cell lymphoma

2018

cancer, kinase inhibitors, lymphoma, drug therapy, clinical trials

Pak2 Regulates Myeloid Derived Suppressor Cell Development in Mice

2017

immunology, cell biology, gene regulation, cancer immunotherapy, mouse models

A phase II Exploratory Study of PXD-101 Belinostat) followed by zevalin in patients with relapsed aggressive high-risk lymphoma

2017

lymphoma, drug therapy, clinical trials, relapse, treatment